Il-6 binding molecules
US-2024158492-A1 · May 16, 2024 · US
Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
US9260516B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9260516-B2 |
| Application number | US-29619307-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 6, 2007 |
| Priority date | Apr 7, 2006 |
| Publication date | Feb 16, 2016 |
| Grant date | Feb 16, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present inventors studied the effects of inhibiting the IL-6 signaling pathway on muscle cell growth. As a result, they discovered that, administering an IL-6 inhibitor can promote the adhesion, proliferation, and differentiation of satellite cells and therefore muscle regeneration.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for promoting muscle regeneration in a subject affected with muscle atrophy, which comprises the steps of: selecting a subject having muscle atrophy caused by an absence of gravitational loading or disuse muscle atrophy; subsequently administering to the subject an effective amount of an IL-6 inhibitor antibody that binds to an IL-6 receptor, inhibits IL-6 from binding to the IL-6 receptor, and further inhibits the IL-6 signaling pathway; and subsequently re-loading the subject's atrophied muscles for at least 7 days. 2. The method of claim 1 , wherein the antibody is a monoclonal antibody. 3. The method of claim 1 , wherein the antibody is an antibody that recognizes human IL-6 receptor. 4. The method of claim 1 , wherein the antibody is a recombinant antibody. 5. The method of claim 1 , wherein the antibody is a chimeric, humanized, or human antibody. 6. The method of claim 1 , wherein the antibody is MR16-1, PM-1, AUK12-20, AUK64-7, or AUK146-15. 7. The method of claim 1 , wherein the selecting step further comprises selecting a subject having muscle atrophy caused by a microgravity space environment, long-term bed rest, or a plaster cast-immobilized state.
Assignees
Inventors
Classifications
IL-6 · CPC title
comprising antibodies · CPC title
against receptors for cytokines, lymphokines, interferons · CPC title
- C07K16/248Primary
IL-6 · CPC title
Drugs for disorders of the muscular or neuromuscular system · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9260516B2 cover?
- The present inventors studied the effects of inhibiting the IL-6 signaling pathway on muscle cell growth. As a result, they discovered that, administering an IL-6 inhibitor can promote the adhesion, proliferation, and differentiation of satellite cells and therefore muscle regeneration.
- Who is the assignee on this patent?
- Nishimoto Norihiro, Ohira Yoshinobu, Univ Osaka
- What technology area does this patent fall under?
- Primary CPC classification C07K16/248. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).